UK Stem Cell Bank - Third Phase

2002年，英国政府规定，应建立一个人类胚胎细胞系库，以监督这些细胞的使用，确保在英国使用的任何这种类型的细胞都是合乎道德的，并且只用于治疗严重人类疾病的研究。此外，世行应提供这些细胞系的质量控制库存，以提供高质量的国际资源，支持英国的干细胞社区，并进一步在再生医学中使用这些细胞。世行在支持干细胞疗法从实验室走向临床方面的作用，已被确认为由约翰·帕蒂森爵士编写并被政府接受的《英国干细胞倡议报告》的关键要素。在下一阶段的资助（第三阶段），世行的目标是保持和发展其作为符合国际质量标准的、来源合乎道德和特征良好的人类干细胞系储备库的首要地位。在第二阶段，世行的主要重点是学术研究，而在第三阶段，世行将与将研究成果转化为治疗应用的科学计划、再生医学临床社区和开发人类细胞培养模型的科学计划进行更密切的协调，以提高新药开发的效率，从而降低成本并提高患者安全性。世行将继续发挥其国际作用，通过以下方式支持干细胞治疗的发展：提供有质量保证和安全测试的细胞系和其他产品，支持研究人员和临床应用;？它继续在最佳实践方面发挥领导作用，并为提供高质量和安全的干细胞制定国际共识标准;为支持英国不断发展的再生医学行业，为干细胞科学家、技术人员和质量保证人员制定培训计划;？它的科学合作和内部研究计划，以建立强大的细胞扩增，分化，保存和表征，这将提高为研究提供的材料的质量，并为临床应用提供更好的方法学途径。计划银行现在将实施其作为国家资源和国际专业知识中心的地位，以支持再生医学的发展，英国的产品安全。

In 2002 the UK Government established that a Bank of human embryonic cell lines should be established to oversee the use of these cells to ensure that any cells of this type, used in the UK were obtained ethically and only used in research for the benefit of treatment of serious human disease. In addition the Bank should provide access to quality-controlled stocks of these cell lines to provide a high quality international resource in support of the UK s stem cell community and to further the use of these cells in regenerative medicine. Such a role for the Bank in supporting the move of stem cell therapies from the laboratory to the bedside was confirmed to be a key element in the UK Stem Cell Initiative Report prepepared by Sir John Pattison and accepted by the Government. In the next phase of funding (Phase III) the Bank aims to sustain and develop its position as the foremost repository of ethically-sourced and well characterised stocks of human stem cell lines banked to international quality standards. Whilst in Phase II the primary focus of the Bank was on academic research, Phase III will see the Bank coordinating more closely with scientific programmes translating research developments into therapeutic applications, the regenerative medicine clinical community and those developing human cell culture models to improve the efficiency of development of new drugs to reduce costs and increase patient safety. The Bank will continue to develop its international role in supporting the development of stem cell therapy through:? the provision of quality-assured and safety tested cell lines and other products supporting researchers and clinical applications;? its continued lead on best practice and the setting of international consensus standards for the delivery of high quality and safe stem cells;? its developing training programme for stem cell scientists, technical staff and quality assurance personnel in support of the UK s developing regenerative medicine industry;? its scientific collaborations and internal research programme to establish robust methodologies for cell expansion, differentiation, preservation and characterisation which will improve the qulity of materials supplied for research and provide improved methodological approaches for clincial application.It is intended that the Bank will now implement its position as a national resource and international centre of expertise in support of the development of regenerative medicines and product safety in the UK.